Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Bear Stearns Cuts Inveresk Research to 'Peer Perform'

Bear Stearns downgraded Inveresk Research (IRGI) to peer perform from outperform.

Analyst Stephan Unger says Inveresk achieved his $19 target. He says the stock has risen 27% since Inveresk reported generally in-line first-quarter results on April 30. This is likely due to broader market advancement and the company's expected inclusion in the Russell 2000 index, he says.

While Inveresk's Montreal preclinical operations appear to have improved, Unger says he doesn't see big upside potential to his $60.3 million revenue and $15.2 million EBITDA second-quarter estimates. Without meaningful advancement in drug stocks (of which the pharmaceutical services group is highly correlated), he sees minimal potential for a near-term price rise.

Unger thinks the current fair value is near $17, which is 15 times the forward earnings per share estimate of $1.14.

blog comments powered by Disqus